facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • FDA has accepted Selvita's IND application for the SEL24 Phase I/II clinical trial in AML

    Kraków, Poland, 18 August 2016 – Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has received an acceptance for its IND application from the U.S. Food and Drug Administration (FDA) for SEL24, the first compound to…

    Read More...

  • Selvita exhibits at ChemOutsourcing 2016

    Krakow, 17 August 2016 - Selvita will participate and exhibit at the upcoming Pharma ChemOutsourcing 2016 conference, which will take place 19 - 21 September 2016, in The Hilton Hotel in Parsippany, NJ.   ChemOutsourcing is the largest USA-based AP…

    Read More...

  • Selvita signs a significant collaboration with the University of California, San Francisco (UCSF)

    Kraków, Poland – 09 August 2016 – Selvita Inc., the US subsidiary of Selvita S.A., headquartered in Cambridge, MA, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF).    project will be cond…

    Read More...